Trial site
Sun Yet-Sen University Cancer Center
Guangzhou, Guangdong 510060, ChinaNot linked to an institution yet
- 10running trials
- 6closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 23 trials
- Phase 1/22 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Active, not recruiting6 trials
- Completed6 trials
- Not yet recruiting2 trials
- Recruiting2 trials
- Lead sponsor
- Hoffmann-La Roche11 trials
- Shanghai Gynecologic Oncology Group2 trials
- Axter Therapeutics (Beijing) Co., Ltd1 trial
- Jiangsu HengRui Medicine Co., Ltd.1 trial
- Wen-zhao ZHONG1 trial
Running trials
Recruiting
AXT-1003 Combination With Enzalutamide in Participants With mCRPC
NCT07897071· Phase 1· Axter Therapeutics (Beijing) Co., Ltd· Source
Contact: Sara Hua, APM
Not yet recruiting
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
NCT07038460· Phase 2· Wen-zhao ZHONG· Source
Contact: Hong Yang
Recruiting
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05533775· Phase 1/2· Hoffmann-La Roche· Source
Recruiting
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260· Phase 2· Shanghai Gynecologic Oncology Group· Source
Contact: Chuyao Zhang
Active, not recruiting
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499· Phase 2/3· Hoffmann-La Roche· Source
Active, not recruiting
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT02859038· Phase 3· Shanghai Gynecologic Oncology Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error